Jeff Reese
Last active: 1/7/2021

is associated with indomethacin treatment failure for patent ductus arteriosus.

Rooney SR, Shelton EL, Aka I, Shaffer CM, Clyman RI, Dagle JM, Ryckman K, Lewis TR, Reese J, Van Driest SL, Kannankeril PJ
Pharmacogenomics. 2019 20 (13): 939-946

PMID: 31486736 · PMCID: PMC6817966 · DOI:10.2217/pgs-2019-0079

To identify clinical andgenetic factors associated with indomethacin treatment failure in preterm neonates with patent ductus arteriosus (PDA). This is a multicenter cohort study of 144 preterm infants (22-32 weeks gestational age) at three centers who received at least one treatment course of indomethacin for PDA. Indomethacin failure was defined as requiring subsequent surgical intervention. In multivariate analysis, gestational age (AOR 0.76, 95% CI 0.60-0.96), surfactant use (AOR 9.77, 95% CI 1.15-83.26), and (AOR 3.74; 95% CI 1.34-10.44) were each associated with indomethacin failure. Age, surfactant use, and influence indomethacin treatment outcome in preterm infants with PDA. This combination of clinical and genetic factors may facilitate targeted indomethacin use for PDA.

MeSH Terms (14)

Cohort Studies Cyclooxygenase Inhibitors Cytochrome P-450 CYP2C9 Ductus Arteriosus, Patent Female Gestational Age Humans Indomethacin Infant Infant, Newborn Infant, Premature Male Treatment Failure Treatment Outcome

Connections (1)

This publication is referenced by other Labnodes entities: